3 completed, 3 recruiting, 3 unknown. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Second-line Treatment: new trials by email Literature Review of Second-line Treatment trials Research Report on Second-line Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02) Second-Line Chemotherapy, Radiation Therapy, Cadonilimab (AK104) - Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer | Phase 3 | Recruiting | Fudan University | 198 | 2026-10-01 | 2026-10-13 |
| Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma Albumin-bound Paclitaxel, Immune Checkpoint Inhibitor, Anti-angiogenic drug - Gastric Cancer, Second-line Treatment | Recruiting | Fudan University | 250 | 2025-09-01 | 2026-02-05 | |
| Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma Fruquintinib - Hepatocellular Carcinoma, Immune Checkpoint Inhibitors | Phase 2 | Recruiting | Sun Yat-sen University | 36 | 2024-12-27 | 2024-12-31 |
| Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer HDR brachytherapy (30Gy single fraction), Immunotherapy - Advanced Stage NSCLC, Second-line Treatment | Unknown | The First People's Hospital of Neijiang | 80 | 2023-09-01 | 2024-07-24 | |
| Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC Cadonilimab - Immunotherapy, Second-line Treatment | Phase 2 | Unknown | Second Affiliated Hospital of Zunyi Medical University | 30 | 2023-01-01 | 2023-06-18 |
| Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC CTL, Toripalimab - Non-small Cell Lung Cancer, Second-line Treatment | Phase 1 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 10 | 2019-06-01 | 2020-07-07 |
| A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Apatinib - Intrahepatic Cholangiocarcinoma, Second-line Treatment | Phase 2 | Completed | Peking Union Medical College Hospital | 34 | 2017-08-08 | 2020-12-02 |
| Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer Paclitaxel and ramucirumab - Gastric Cancer Stage IV, Second-line Treatment | Completed | Hellenic Cooperative Oncology Group | 185 | 2015-03-01 | 2024-10-30 | |
| A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer TKI258 - Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 53 | 2011-11-01 | 2015-05-20 |
Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Stomach Neoplasms (2) · Barakat syndrome (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2)
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Ado-Trastuzumab Emtansine (1) · Albumin-Bound Paclitaxel (1) · Angiogenesis Inhibitors (1) · Drug Therapy (1) · HMPL-013 (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy (1) · Paclitaxel (1) · Radiotherapy (1) · Ramucirumab (1) · apatinib (1) · toripalimab (1)
Fudan University (2) · Hellenic Cooperative Oncology Group (1) · Novartis Pharmaceuticals (1) · Peking Union Medical College Hospital (1) · Second Affiliated Hospital of Zunyi Medical University (1) · Sun Yat-sen University (1) · The First People's Hospital of Neijiang (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (7) · Brazil (1) · Greece (1) · Italy (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
Hai-tao Zhao (1) · Hu Ma, Ph.D (1) · Xiubao Ren, M.D, Ph.D (1)
PMID 25754329, PMID 25799953, PMID 25981814, PMID 28094262, PMID 28577836, PMID 29945993, PMID 30093664, PMID 30619280, PMID 30642458, PMID 31154919, PMID 33872070, PMID 33891980, PMID 34970277, PMID 35108059, PMID 35143424, PMID 35906199, PMID 35980349, PMID 38706247